HER2-Directed Therapies in NSCLC: Navigating Clinical Insights, Integration Challenges, and Access Considerations : Episode 12

Opinion

Video

November 27, 2024

Managing Treatment Challenges in HER2-Directed Therapies

Key Takeaways

Understanding molecular mechanisms of resistance is crucial for developing novel therapeutic agents and combination strategies in HER2-directed therapies.
Personalized medicine, utilizing genomic profiling, is expected to tailor treatments to individual patient profiles, enhancing efficacy.
Integrating immunotherapy with targeted therapies may provide synergistic effects, improving treatment outcomes.
Continuous clinical trials and translational research are essential to refine strategies and improve patient outcomes in HER2-directed therapies.

SHOW MORE

An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.

EP: 1.Introduction and Current Landscape of HER2 in NSCLC

EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC

EP: 3.Treatment Considerations for Patients With HER2+ NSCLC

EP: 4.Latest Advances and Therapies for HER2+ NSCLC

EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC

EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC

EP: 7.HER2- Mutation Testing Considerations and Timing

EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC

EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC

EP: 10.Key Takeaways on the Future of HER2 in NSCLC

EP: 11.Real-World Outcomes in HER2-Positive NSCLC

EP: 12.Managing Treatment Challenges in HER2-Directed Therapies

EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments

EP: 14.Patient Selection and Personalized Treatment Strategies

EP: 15.Navigating Healthcare Access and Decision-Making

Video content above is prompted by the following:

How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?

Related Videos

1 expert in this video

1 expert in this video

Dr Margrit Wiesendanger

4 experts are featured in this series.

5 experts in this video

4 experts are featured in this series.

5 experts in this video

1 expert in this video

1 expert in this video

Related Content

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.

AJMC

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

Related Content

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.

AJMC

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions